Abstract: A composition is intended to form on the skin, by spraying from an erasol can, a film for the transdermal administration of an active agent, and the composition contains 0.01-10% by weight of lipophilic vitamins, hormones, nicotine, corticoids, retinoids, antimycosic agents, anistetics, anolgesics, or anti cancer agents for the skin, 0.5 to 25% by weight of an adhesive polysiloxane composition, 5 to 25% by weight of an absorption promoter, 25 to 95% by weight of a volatile solvent containing at least a volatile silicone, and 0.5 to 50% by weight of pressurized propellant gas, and the composition is substantially free from water.

Abstract: The present invention discloses a method for treating Streptococcal infections of the upper respiratory tract, comprising administering an effective amount of a lysin enzyme produced by group C Streptococcal bacteria infected with a C1 bacteriophage specific for the bacteria to a mouth, throat, or nasal passage of a mammal, the method providing a concentration of from about 100 to 500,000 active enzyme units per milliliter of fluid in the environment of said nasal or oral passages.

Abstract: An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual.

Abstract: Crushable gel beads 10 formed of an agar complex provide novel cosmetic, pharmaceutical, etc. delivery vehicles for topical delivery of biologically or cosmetically active agents. Preferred agar beads 10 are complexes of a continuous phase of agar gel 12 in a self-supporting solid or semi-solid form with a restraining polymer 14. Entrapped in and dispersed randomly throughout each agar bead 10 is a water-soluble, preferably polar, restraining polymer 14, preferably a quaternized cationic polymer, such as polyquaternium 24 or steardimonium hydroxyethylcellulose. Various active agents 16 may be bound to restraining polymer 14, for example ascorbic acid, lactic acid or papain. Methods of manufacture are also described.

Abstract: A medicinal aerosol steroid solution formulation product with enhanced chemical stability. The steroid is a 20-ketosteroid having an OH group at the C-17 or C-21 position and the aerosol container has a non-metal interior surface which has been found to reduce chemical degradation of such steroids.

Abstract: A method of preventing damage caused to healthy skin, hair or mucous membranes by free radicals, includes applying to the healthy skin, hair or mucous membrane a composition containing at least one product having a peroxidase activity capable of reducing organic peroxides and at least one antioxidant capable of neutralizing singlet oxygen, the composition being free of peroxide. The product having a peroxidase activity is present in an amount of from 0.005 to 5.0% by weight, and the antioxidant is present in an amount of from 0.005 to 3.0% by weight, with a weight ratio of the product having a peroxidase activity to the antioxidant of from 0.001 to 0.3. The product having a peroxidase activity capable of reducing organic peroxides is lactoperoxidase, and the antioxidant is selected from quinolines, polyphenols, and carotenoids.

Abstract: A pressurized container with an aerosol pharmaceutical formulation, and a process for making the formulation, are provided. The formulation comprises a pharmaceutical agent, a phenol, glycerin or polyglycerin, and an additional ingredient such as an alkali metal alkyl sulfate, polidocanol alkyl ether or the like. The formulation is placed in the pressurized container, which is then charged with a propellant. A method of treating a medical condition, by spraying the formulation into the mouth or lungs, is also provided.

Abstract: A mixed micellar aerosol pharmaceutical formulation is provided. The formulation comprises a pharmaceutical agent, an alkali metal alkyl sulphate, at least three micelle-forming compounds, a phenol and a propellant. The propellant provides enchanced absorption of the pharmaceutical agent in the buccal region. A process of making and a method of administering the composition are also included.

Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a hydrofluoroalkane propellant. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as, by settling or flocculation. In particularly preferred embodiments, the stabilized dispersions may be administered to the lung of a patient using a metered dose inhaler.

Abstract: The S-isomer of a compound represented by the following formula: and pharmaceutically acceptable salts thereof is disclosed as being useful for treating urinary disorders, including urinary incontinence, and gastrointestinal disorders, including gastrointestinal hyperativity.

Abstract: This invention relates to aerosol formulations of use in the administration of medicaments by inhalation. In particular, the formulations comprise (a) 1,1,1,2-tetrafluoro-ethane or 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof as propellant, (b) 1,1,2,2,3-pentafluoropropane as co-propellant, and (c) particulate medicament. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the pharmaceutical aerosol formulation is also described, as well as is a canister which is suitable for delivering the pharmaceutical aerosol formulation.

Abstract: Composition and methods that include potassium nitrate for whitening and/or reducing tooth sensitivity. The dental compositions may optionally include a dental bleaching agent, such as hydrogen peroxide or carbamide peroxide. The dental compositions may be applied directly to the person's teeth, or they may be loaded into a comfortable fitting, flexible, thin-walled dental tray and placed over the person's teeth. In that case, the dental compositions will include a tackifying agent, such as carboxypolymethylene, dispersed within a solvent, which assists the composition in retaining the dental tray over the person's teeth as a result of the adhesive properties of the dental composition rather than due to mechanical interlocking of the tray over the person's teeth. The dental compositions may further include anticariogenic and antimicrobial agents.

Abstract: Composition and methods that include potassium nitrate for whitening and/or reducing tooth sensitivity. The dental compositions may optionally include a dental bleaching agent, such as hydrogen peroxide or carbamide peroxide. The dental compositions may be applied directly to the person's teeth, or they may be loaded into a comfortable fitting, flexible, thin-walled dental tray and placed over the person's teeth. In that case, the dental compositions will include a tackifying agent, such as carboxypolymethylene, which assists the composition in retaining the dental tray over the person's teeth as a result of the adhesive properties of the dental composition rather than due to mechanical interlocking of the tray over the person's teeth. The dental compositions may further include anticariogenic and antimicrobial agents.

Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when said formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.

Abstract: A time-release laminar pharmaceutical composition, comprised of rolled or folded layers of a polymer film, that contain a pharmaceutically active substance, in which the outer surface area of the polymer film which contains the active substance, and which is accessible to the digestive juices, amounts to at most 25% of the entire surface area in the rolled or folded state, and the rolled or folded layers adhere to one another in such a way that the laminar form of medication maintains its rolled or folded form for a period of at least one hour in the release test according to USP 23, Method A, apparatus 2, at 37° C. and 50 rpm, in artificial gastric juice, and at least 30% of the active substance contained in it is released in the rolled or folded state.

Abstract: Aerosol formulations comprising: (A) A medicament in particulate form and having a surface coating of a surfactant; (B) A hydrogen-containing fluorocarbon or chlorofluorocarbon propellant; and (C) A cosolvent having higher polarity than the propellant which cosolvent is present in an amount of up to 5% w/w based upon propellant; and methods for their preparation.

Abstract: The invention relates to a composition, in pellet form, useful for the nutritional and/or medicinal supplementation of ruminants and a method for admixing the pellets with foodstuff. The pellet contains granules of one or more active ingredients/principles protected against degradation in toe rumen and one or more binding agents capable of being solubilized, crosslinked or melted. Optionally, the pellet may also contain an unprotected active ingredient for release in the rumen. The pellet may further contain a disintegrating agent and/or filler.

Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.

Abstract: The invention disclosed relates to the delivery of a sanitizer to a personal use surface, such as a toilet seat surface. A dispensing unit is provided for delivery of the sanitizer as an aerosol spray, leaving only the sanitizer in pure form on the seat surface. This results in quick drying of the surface in 12-15 seconds.

Abstract: A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased duration of action.